pomalidomide has been researched along with Kahler Disease in 389 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (5.40) | 29.6817 |
| 2010's | 240 (61.70) | 24.3611 |
| 2020's | 128 (32.90) | 2.80 |
| Authors | Studies |
|---|---|
| Baculi, F; Carmel, G; Condroski, K; Correa, M; Crea, T; Hansen, JD; Hickman, M; LeBrun, L; Liu, W; Lu, CC; Lu, G; Mahmoudi, A; Man, HW; Muller, G; Ruchelman, A; Vocanson, F; Zhang, W | 1 |
| Baculi, F; Carmel, G; Carmichael, J; Cathers, BE; Chamberlain, PP; Daniel, TO; Hickman, M; Khambatta, G; LeBrun, L; Lu, CC; Lu, G; Man, HW; Matyskiela, ME; Muller, G; Pagarigan, B; Riley, M; Satoh, Y; Schafer, P; Zhang, W | 1 |
| Barinka, C; Leisten, ED; Li, Z; Liu, J; Novakova, Z; Smith, KA; Tang, W; Wu, H; Xie, H; Yang, K; Zhang, Z | 1 |
| Alexander, M; Baculi, F; Carmichael, J; Cathers, B; Correa, M; Daniel, T; Ebinger, K; Grant, V; Hamann, LG; Hansen, JD; Harris, R; Havens, CG; Huang, D; Kercher, T; Khambatta, G; LeBrun, LA; Leftheris, K; Leisten, J; Lopez-Girona, A; Mendy, D; Moghaddam, M; Nagy, MA; Narla, RK; Piccotti, J; Plantevin, V; Tang, Y; Vessey, R; Whitefield, B | 1 |
| Hogan, L; Kim, MJ; Lassalle-Claux, G; Luiker, K; Murugesan, A; Reiman, T; Selka, A; Touaibia, M; Vaillancourt, E | 1 |
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Anderson, KC; Birsner, AE; D'Amato, RJ; LeBlanc, R; Lentzsch, S; Rogers, MS; Shah, JH; Treston, AM | 1 |
| Chim, CS; Kumar, S; Kwong, YL; Ngai, C; Wong, VKC | 1 |
| Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M | 1 |
| Bringhen, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Le-Guennec, S; Macé, S; Richardson, PG; Schjesvold, F; Yong, K | 1 |
| Abdallah, AO; Arriola, E; Bowles, KM; Bueno, OF; Coppola, S; Gasparetto, C; Mander, G; Mateos, MV; Morris, L; Ross, JA; Wang, J | 1 |
| Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM | 1 |
| Antonioli, E; Attucci, I; Bocchia, M; Buda, G; Candi, V; Ciofini, S; Del Giudice, ML; Fontanelli, G; Formica, G; Galimberti, S; Ghio, F; Gozzetti, A; Orciuolo, E; Petrini, M | 1 |
| D'Rozario, J; Estell, J; Ho, PJ; Kalff, A; Kemp, R; Kennedy, N; Khong, T; Mitchell, AJ; Mollee, P; Norton, S; Quach, H; Ramachandran, M; Reynolds, J; Spencer, A; Taylor, K | 1 |
| Alegre, A; Beksac, M; Campana, F; Finn, G; Goodman, HJ; Hulin, C; Le-Guennec, S; Macé, S; Muccio, S; Prince, M; Richardson, PG; Rouchon, MC; Spicka, I; Tavernier, A | 1 |
| Ayral, G; Cerou, M; Fau, JB; Gaudel, N; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C | 1 |
| Hino, M; Koh, H; Kuno, M; Makuuchi, Y; Nakamae, H; Nakashima, Y; Nishimoto, M; Ohta, K; Okamura, H; Sogabe, N; Takakuwa, T | 1 |
| Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D | 1 |
| Ide, T; Osawa, M; Sanghavi, K; Vezina, HE | 1 |
| Fulzele, KS; Kato, H; Maebius, A; Mori, T; Mukaihara, K; Nakamoto-Matsubara, R; Onyewadume, C; Panaroni, C; Raje, NS; Sadreyev, RI; Scadden, DT; Siu, KT; Verma, R; Wong, LP | 1 |
| Adelman, K; Amaka, S; de Leval, L; Donaldson, NL; Donovan, KA; Duffy, J; Fischer, ES; Gaulard, P; Hagner, PR; Heavican-Foral, TB; Iqbal, J; Jain, S; Jones, MK; Koch, R; Liu, H; Nelson, GM; Ng, SY; Nirmal, AJ; Nowak, RP; Powers, F; Stevenson, KE; Thakurta, A; Trevisani, C; Weinstock, DM; Wu, G; Wu, W; Xu, R; Yang, L | 1 |
| Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M | 1 |
| Ji, J; Li, J; Li, Y; Lu, H; Qu, X | 1 |
| Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A | 1 |
| Amin, H; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Fastenau, J; Gries, KS; He, J; Kampfenkel, T; Katodritou, E; Liu, K; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Pompa, A; Qiu, Y; Sonneveld, P; Symeonidis, A; Terpos, E | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K | 1 |
| Anderson, L; Basu, S; Djebbari, F; Eyre, TA; Maddams, R; Poynton, M; Ramasamy, K; Sangha, G; Vallance, G | 1 |
| Anderson, KC; Beksac, M; Cavo, M; Dimopoulos, MA; Dubin, F; Huang, JS; Leleu, X; Malinge, L; Minarik, J; Moreau, P; Perrot, A; Prince, HM; Richardson, PG; San-Miguel, J; Schjesvold, F; Spicka, I; van de Velde, H | 1 |
| Alegre, A; Bensfia, S; Bringhen, S; Campana, F; Facon, T; Frenzel, L; Guillonneau, S; Jurczyszyn, A; Le-Guennec, S; Lin, PL; Min, CK; Richardson, PG; Schjesvold, F; Spencer, A; Sunami, K; Van de Velde, H | 1 |
| Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C | 1 |
| Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K | 1 |
| Gogia, A; Gupta, R; Kumar, L; Kumar, S; Malik, PS; Pathak, N; Prasad, CP; Sahoo, RK; Sharma, A | 1 |
| Akahoshi, Y; Gomyo, A; Kako, S; Kameda, K; Kanda, Y; Kawamura, M; Kawamura, S; Kimura, SI; Kusuda, M; Matsumi, S; Misaki, Y; Nakamura, Y; Nakasone, H; Okada, Y; Takeshita, J; Tamaki, M; Tanihara, A; Yoshimura, K; Yoshino, N | 1 |
| Campana, F; Huang, SY; Iida, S; Ikeda, T; Iyama, S; Kaneko, H; Kim, JS; Kim, K; Koh, Y; Lee, JH; Lin, TL; Matsumoto, M; Min, CK; Shimazaki, C; Sunami, K; Suzuki, K; Tada, K; Uchiyama, M; Wang, MC; Yeh, SP | 1 |
| Anderson, L; Basker, N; Basu, S; Bygrave, C; Chauhan, SR; Djebbari, F; Eyre, TA; Firas, AK; Gudger, A; Karim, F; Lam, HPJ; Maddams, R; Morgan, L; Ngu, L; Obeidalla, A; Panitsas, F; Poynton, M; Prideaux, S; Ramasamy, K; Rampotas, A; Salhan, B; Sangha, G; Soutar, R; Triantafillou, M; Tsagkaraki, I; Vallance, G; Walker, M; Yang, L; Young, J | 1 |
| Bai, H; Fang, BJ; Fu, WJ; Liao, AJ; Lu, J; Niu, T; Wang, YF; Zhao, HG | 1 |
| Bathija, S; Berringer, H; Dwarakanathan, HR; He, J; Heeg, B; Johnston, S; Kampfenkel, T; Lam, A; Mackay, E; Mendes, J; Ruan, H | 1 |
| Afari, J; Berenson, JR; Bessudo, A; Cohen, A; Eades, BM; Eshaghian, S; Gabrail, N; Jhangiani, H; Kim, C; Kim, S; Kubba, S; Neidhart, JD; Spektor, TM; Swift, RA; Turner, C; Vescio, R | 1 |
| Das, P; Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Richardson, PG; San-Miguel, J; Suzuki, K; Takezako, N; Yao, D | 1 |
| Alizadeh, H; Illés, Á; Lovas, S; Mikala, G; Obajed Al-Ali, N; Plander, M; Rajnics, P; Szemlaky, Z; Szita, V; Varga, G; Váróczy, L | 1 |
| Chen, XM; Huang, CL; Liao, KY; Liu, Y; Xiong, H; Zhang, XW | 1 |
| Amin, H; Carson, R; Dimopoulos, MA; Dosne, AG; Kampfenkel, T; Li, X; Luo, MM; Nnane, I; Perez Ruixo, J; Sonneveld, P; Sun, YN; Terpos, E; Xu, Y; Zhou, H | 1 |
| Čápková, L; Hájek, R; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecka, V; Ševčíková, S; Špička, I; Štork, M; Štraub, J; Wróbel, M | 1 |
| Aebi, S; Driessen, C; Goede, J; Hayoz, S; Lerch, E; Maniecka, Z; Mey, U; Novak, U; Pabst, T; Renner, C; Rhyner Agocs, G; Rüfer, A; Schär, S; Zander, T | 1 |
| Ancel, J; Deslee, G; Dury, S; Godet, S; Launois, C; Perotin, JM; Vivien, A | 1 |
| Abdallah, AO; Ahmed, N; Atrash, S; Cui, W; Hashmi, H; Jain, J; Khasawneh, G; Mahmoudjafari, Z; McGuirk, J; Mohan, M; Shune, L | 1 |
| Al-Kaisi, F; Anderson, L; Basker, N; Basu, S; Bygrave, C; Chauhan, SR; Djebbari, F; Eyre, TA; Gudger, A; Karim, F; Kothari, J; Lam, HPJ; Maddams, R; Morgan, L; Ngu, L; Obeidalla, A; Panitsas, F; Poynton, M; Prideaux, S; Ramasamy, K; Rampotas, A; Salhan, B; Sangha, G; Soutar, R; Triantafillou, M; Tsagkaraki, I; Vallance, G; Walker, M; Yang, L; Young, J | 1 |
| Abe, O; Ikemura, M; Kurokawa, M; Maki, H; Masamoto, Y; Miwa, A; Morita, K; Nakazaki-Watadani, K; Obo, T; Sumida, Y; Takami, H; Takayanagi, S; Tanaka, S; Yasaka, K | 1 |
| Berdeja, J; Cole, C; Derman, BA; Griffith, K; Jakubowiak, AJ; Jasielec, J; Kin, A; Major, A; Reece, D; Stefka, AT; Zonder, J | 1 |
| Binder, M; Brioli, A; Engelhardt, M; Ernst, T; Gengenbach, L; Heidel, FH; Hilgendorf, I; Hochhaus, A; Mancuso, K; Stauch, T; von Lilienfeld-Toal, M; Zamagni, E | 1 |
| Dubashi, B; Ganesan, P; Halanaik, D; Kar, R; Kayal, S; Nisha, Y; Saj, F | 1 |
| Araujo, C; Attal, M; Belhadj, K; Berge, B; Chaleteix, C; Devlamynck, L; Escoffre-Barbe, M; Facon, T; Garderet, L; Hulin, C; Ikhlef, S; Karlin, L; Kuhnowski, F; Lafon, I; Leleu, X; Lenain, P; Loiseau, HA; Macro, M; Moreau, P; Perrot, A; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Tiab, M | 1 |
| Du, J; Fu, WJ; Guo, P; He, HY; Jiang, H; Li, L; Liu, J; Lu, J; Qiang, WT | 1 |
| Buadi, F; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, R; Gonsalves, W; Hayman, S; Hobbs, M; Hwa, Y; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Muchtar, E; Rajkumar, SV; Siddiqui, M; Vaxman, I; Warsame, R | 1 |
| Chen, H; Xu, W; Xu, Y; Yu, J; Zhou, F; Zhou, Y | 1 |
| Abdulhaq, H; Bakker, NA; Dimopoulos, MA; Hájek, R; Ludwig, H; Mateos, MV; Norin, S; Richardson, PG; Schjesvold, FH; Sonneveld, P; Thuresson, M | 1 |
| Fu, CC; Jin, S; Ma, X; Shang, JJ; Wang, J; Wu, DP; Yao, Y | 1 |
| Bekri, S; Cho, HJ; Costa, LJ; Hamidi, H; Neparidze, N; Nielsen, TG; Raval, A; Sareen, R; Vij, R; Wassner-Fritsch, E; Wong, S | 1 |
| Davies, FE; Dhanasiri, S; Le Nouveau, P; Leleu, X; Vogel, P; Weisel, K | 1 |
| Chen, C; Fiala, MA; Gao, F; King, J; Kirchmeyer, M; Schroeder, MA; Slade, M; Stewart, AK; Stockerl-Goldstein, K; Vij, R | 1 |
| Chu, XX; Wang, J; Wang, W; Xu, H | 1 |
| Boyle, J; Bright, S; Capra, M; Chraniuk, D; Currie, B; Delimpasi, S; Dimopoulos, MA; He, W; Hungria, VTM; Leleu, X; Li, J; Li, M; Low, M; Maiolino, A; Masszi, T; Matsumoto, M; McKeown, A; Mikala, G; Opalinska, J; Osipov, I; Pappa, V; Perera, S; Radinoff, A; Roy-Ghanta, S; Sule, N; Weisel, K | 1 |
| Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Kosh, M; Liu, W; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Sonneveld, P; Symeonidis, A; Terpos, E; Tran, N; Wang, J | 1 |
| Chu, XX; Deng, XZ; Fan, CB; Hao, HY; Liu, GQ; Ran, XH; Wu, HY; Yuan, CL; Zhong, YP; Zhou, X | 1 |
| Atieh, T; Faiman, B; Hubben, A; Khouri, J; Samaras, CJ; Valent, J | 1 |
| Bulla, A; Conticello, C; Cupri, A; Curto Pelle, A; Di Giorgio, MA; Leotta, S; Leotta, V; Markovic, U; Martino, EA; Milone, G; Pirosa, MC; Sapienza, G; Scalise, L; Vaddinelli, D; Villari, L | 1 |
| Mo, CC; Richardson, PG | 1 |
| Agajanian, R; Agarwal, A; Bahlis, NJ; Chung, W; Kaya, H; Malek, E; Mouro, J; Pierceall, WE; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, KW; Srinivasan, S; Stockerl-Goldstein, K; Talamo, G; Zafar, F | 1 |
| Asaoku, H; Chim, CS; Chng, WJ; Durie, B; Gopalakrishnan, SK; Huang, SY; Kim, JS; Kim, K; Kimura, H; Kosugi, H; Lee, JH; Lee, JJ; Lee, SL; Min, CK; Moorakonda, R; Nagarajan, C; Sakamoto, J; Soekojo, CY; Takezako, N; Wei, Y; Yoon, SS | 1 |
| Amatangelo, M; Bjorklund, CC; Chiu, H; Couto, S; Flynt, JE; Kang, J; Katz, M; Ortiz, M; Pierceall, W; Polonskaia, A; Ren, Y; Thakurta, A; Towfic, F; Wang, M | 1 |
| Trudel, S | 1 |
| Anderson, KC; Attal, M; Beksac, M; Campana, F; Cavo, M; Corzo, KP; Dimopoulos, MA; Dubin, F; Huang, JS; Le-Guennec, S; Leleu, X; Macé, S; Minarik, J; Moreau, P; Prince, HM; Rajkumar, SV; Richardson, PG; San-Miguel, J; Schjesvold, F; Spicka, I | 1 |
| Delimpasi, S; Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Giannouli, S; Kanellias, N; Kastritis, E; Migkou, M; Mparmparousi, D; Ntanasis-Stathopoulos, I; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E; Tsirigotis, P; Xirokosta, A; Ziogas, DC | 1 |
| Cooper, DL; Huang, E; Kane, MP; Monteleone, CA; Park, JJ | 1 |
| Cahn, JY; Courby, S; Deteix, C; Larabi, A; Meunier, M; Schacherer, M | 1 |
| Bai, H; Fan, WJ; Fan, ZQ; Pan, YZ; Yang, K; Yao, H; Yin, JJ; Zhao, XC | 1 |
| Thompson Heffner, L; Waller, E; Woods, A; Wooten, M | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Ohara, S; Uchida, T | 1 |
| Fujii, S; Handa, H; Iida, M; Ito, T; Katayama, M; Sakamoto, S; Suwa, T; Tateno, S; Tokuyama, H; Yamaguchi, Y; Yamamoto, J | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S | 1 |
| Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M | 1 |
| Anttila, P; Basu, S; Ben-Yehuda, D; Biyukov, T; Byeff, P; Cascavilla, N; Dhanasiri, S; Dimopoulos, M; Grote, L; Guo, S; Hayden, PJ; Hus, M; Johnson, P; Kanate, AS; Krauth, MT; Larocca, A; Lucio, P; Mendeleeva, L; Moreau, P; Muelduer, E; Richardson, P; Rodríguez-Otero, P; Vural, F; Weisel, K; Yagci, M; Yu, X | 1 |
| Biyukov, T; Matsue, K; Peluso, T; Richardson, P; Sakurai, S; Shinagawa, A; Sunami, K; Suzuki, K; Takezako, N; Tamakoshi, H | 1 |
| Cornell, RF; Engelhardt, BG; Goldhaber, SZ; Hall, R; Harrell, S; Jagasia, M; Moslehi, J; Piazza, G; Rubinstein, SM; Wyatt, H | 1 |
| Dhillon, S | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F | 1 |
| Badillo, M; Berkova, Z; Chen, W; Feng, L; Jain, P; Manasanch, EE; Oriabure, O; Orlowski, RZ; Wang, M | 1 |
| Ichinohe, T; Ishibashi, H; Kikumto, M; Maruyama, H; Nakamichi, K; Saijo, M; Takahashi, T; Takebayashi, Y; Ueno, H; Umemoto, K; Yasutomi, H | 1 |
| Assadourian, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Leleu, X; Liberati, AM; Malinge, L; Miles Prince, H; Moreau, P; Ocio, EM; Richardson, PG; Sémiond, D; van de Velde, H; Yong, K | 1 |
| Bladé, J; Cejalvo, MJ; de Arriba, F; de la Rubia, J; Dourdil, MV; García-Malo, MD; García-Mateo, A; García-Sanz, R; Lahuerta, JJ; Martín-Sánchez, J; Martínez-López, J; Mateos, MV; Motlló, C; Ocio, EM; Oriol, A; Rodríguez-Otero, P; San-Miguel, JF | 1 |
| Jeon, YH; Kim, GW; Kwon, SH; Lee, DH; Lee, SW; Won, HR; Yeon, SK; Yoo, J | 1 |
| Chinen, Y; Fujibayashi, Y; Gütschow, M; Horiike, S; Isa, R; Kobayashi, T; Kuroda, J; Kuwahara-Ota, S; Matsumura-Kimoto, Y; Mizuno, Y; Nishiyama, D; Shimura, Y; Steinebach, C; Takimoto-Shimomura, T; Taniwaki, M; Tsukamoto, T; Yamaguchi, J | 1 |
| Alegre, A; Bensfia, S; Bringhen, S; Campana, F; Facon, T; Frenzel, L; Guillonneau, S; Jurczyszyn, A; Le-Guennec, S; Lin, PL; Min, CK; Richardson, PG; Schjesvold, FH; Spencer, A; Sunami, K; van de Velde, H | 1 |
| Einsele, H; Grathwohl, D; Kortüm, KM; Krummenast, F; Leicht, HB; Meckel, K; Nickel, K; Rasche, L; Steinhardt, MJ; Zhou, X | 1 |
| Chu, TH; Jung, SH; Kim, HJ; Lakshmi, TJ; Lee, JJ; Park, HS; Vo, MC | 1 |
| Bittrich, M; Danhof, S; Einsele, H; Gisslinger, B; Gisslinger, H; Hefner, J; Hose, D; Knop, S; Krauth, MT; Schoder, R; Schreder, M; Strifler, S | 1 |
| Richardson, PG | 1 |
| Chan, E; Chari, A; Cho, HJ; Couto, S; Florendo, E; Ip, C; Jagannath, S; Kim-Schulze, S; La, L; Laganà, A; Lau, K; Leshchenko, VV; Madduri, D; Mancia, IS; Melnekoff, DT; Parekh, S; Pierceall, WE; Richter, J; Strumolo, G; Thakurta, A; Thomas, J; Van Oekelen, O; Verina, D; Vishnuvardhan, N; Wang, M; Zarychta, K | 1 |
| Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X | 1 |
| Anderson, KC; Arvedson, T; Cho, SF; Friedrich, M; Hsieh, PA; Li, Y; Lin, L; Matthes, K; Munshi, N; Tai, YT; Wahl, J; Wen, K; Xing, L; Yu, T | 1 |
| Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M | 1 |
| Asatsuma-Okumura, T; Handa, H; Ito, T; Kishi, T; Kizaki, M; Mizutome, H; Momose, S; Murase, Y; Shimizu, N; Suwa, T; Tateno, S; Yamaguchi, Y; Yamamoto, J | 1 |
| Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D | 1 |
| Abdallah, AO; Atrash, S; Ganguly, S; Kawsar, H; Mahmoudjafari, Z; McGuirk, J; Mohyuddin, GR; Shune, L; Sigle, M | 1 |
| Beilhack, A; Brandl, A; Köpff, S; Krönke, J; Lindner, S; Ng, YLD; Röhner, L; Scheffold, A | 1 |
| Berenson, JR; Eades, B; Emamy-Sadr, M; Regidor, B; Spektor, TM; Swift, R; Tarhini, F | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, AL; Gertz, MA; Go, RS; Gonsalves, WI; Hayman, SR; Hobbs, MA; Hwa, YL; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; Leung, N; Muchtar, E; Rajkumar, SV; Siddiqui, MA; Warsame, R | 1 |
| van de Donk, NWCJ | 2 |
| Carilli, A; Chahin, A; Comba, IY; Taj, H | 1 |
| Jiang, X; Kan, W; Li, J; Li, Y; Mi, T; Wang, Y; Xu, G; Zhou, Y | 1 |
| Ansari-Pour, N; Bahlis, N; Chamberlain, PP; Dhiman, P; Flynt, E; Gooding, S; Hirst, M; Neri, P; Ortiz Estévez, M; Ramasamy, K; Rozelle, D; Thakurta, A; Towfic, F; Tsai, KT; Vyas, P | 1 |
| Barchnicka, A; Bednarczyk, M; Grosicka, O; Grosicki, S | 1 |
| Chari, A; Delea, TE; Hagiwara, M; Kee, A; Madduri, D; Parikh, K; Pelletier, C | 1 |
| Andriani, A; Annibali, O; Antolino, G; Cantonetti, M; Cimino, G; Coppetelli, U; De Rosa, L; De Stefano, V; di Toritto, TC; La Verde, G; Petrucci, MT; Piciocchi, A; Rizzo, M; Siniscalchi, A; Vozella, F; Za, T | 1 |
| Branagan, AR; Dhodapkar, KM; Dhodapkar, MV; Flavell, RA; Verma, R; Xu, ML | 1 |
| Anupindi, VR; Kudaravalli, S; Richter, J; Shah, D; Yeaw, J; Zavisic, S | 1 |
| Bagal, B; Bonda, A; Bondili, SK; Gokarn, A; Jain, H; Khattry, N; Nayak, L; Punatar, S; Sengar, M; Thorat, J; Ventrapati, P; Zawar, A | 1 |
| Bensinger, WI; Campana, F; Chiron, M; Facon, T; Leleu, X; Macé, S; Mikhael, J; Richardson, PG; van de Velde, H | 1 |
| Bernabei, L; Cohen, AD; Garfall, AL; Gonzalez, VE; June, CH; Lacey, SF; Levine, BL; Melenhorst, JJ; Milone, MC; Plesa, G; Stadtmauer, EA; Tian, L; Vogl, DT; Waxman, A; Young, RM | 1 |
| Blevins, F; Hughes, D; Lerner, A; Milrod, CJ; Sanchorawala, V; Sarosiek, S; Sloan, JM | 1 |
| Anguita, M; Arguiñano, JM; Arnao, M; Bladé, J; Blanchard, MJ; Cabañas, V; Casado, F; de Cabo, E; de Coca, AG; Encinas, C; García, R; González-Rodríguez, AP; Hernández-Rivas, JÁ; Iñigo, B; Lafuente, AP; Lahuerta, JJ; Lavilla, E; López, A; Maldonado, R; Martí, JM; Mateos, MV; Motlló, C; Murillo, I; Pérez-Persona, E; Ribas, P; Rodriguez-Otero, P; Sampol, A; San Miguel, JF; Sirvent, M | 1 |
| Arbab, A; Cotteret, S; Ghez, D; Marzac, C; Saada, V | 1 |
| Benboubker, L; Bringhen, S; Campana, F; Karlin, L; Koh, Y; Le Guennec, S; Maisnar, V; Menas, F; Pavic, M; Pour, L; Richardson, PG; van de Velde, H; Vorobyev, V; Vural, F; Warzocha, K | 1 |
| Ando, K; Farooqui, M; Iida, S; Kher, U; Koh, Y; Kosugi, H; Kuroda, J; Liao, J; Marinello, P; Maruyama, D; Matsuda, K; Matsumoto, M; Shimamoto, T; Sunami, K; Suzuki, K; Taniwaki, M; Tobinai, K | 1 |
| Piggin, A; Prince, HM | 1 |
| Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K | 1 |
| Bensinger, WI; Bianchi, G; Campana, F; D'Souza, A; Dubin, F; Kanagavel, D; Karanes, C; Laubach, JP; Raje, N; Richardson, PG; Saleem, R; Sborov, D; Tuchman, SA; Usmani, SZ | 1 |
| Ahmadi, T; Amin, H; Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Qiu, Y; Schecter, JM; Sonneveld, P; Symeonidis, A; Terpos, E; Ukropec, J; Vermeulen, J | 1 |
| Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Fiala, M; Gao, F; Goldsmith, S; King, J; Liu, L; Schroeder, MA; Stockerl-Goldstein, K; Vij, R; Wildes, TM | 1 |
| Delgado, J; Enzmann, H; Gisselbrecht, C; Moreau, A; Pignatti, F; van Hennik, PB; Zienowicz, M | 1 |
| A Dimopoulos, M; Bringhen, S; Facon, T; Foster, MC; G Richardson, P; Hulin, C; Leleu, X; Moreau, P; Perrot, A; Poole, EM; Schjesvold, F; Tekle, C; van de Velde, H | 1 |
| Copeland, W; Fox, BA; Newhall, KJ; Pietz, G; Thompson, E; Whalen, E; Young, MH | 1 |
| Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ | 1 |
| Badros, A; Dell, C; Dogan, A; Goloubeva, O; Hyjek, E; Kocoglu, M; Lederer, E; Lesokhin, A; Ma, N; Milliron, T; Philip, S; Rapoport, AP; Singh, Z | 1 |
| Anderson, KC; Brooks, CL; Chauhan, D; Das, DS; Macri, V; Ray, A; Richardson, P; Song, Y | 1 |
| Anttila, P; Bahlis, N; Biyukov, T; Cavo, M; Chen, C; Cook, G; Corradini, P; Delforge, M; Dimopoulos, MA; Hansson, M; Herring, J; Hong, K; Joao, C; Kaiser, M; Moreau, P; O'Gorman, P; Oriol, A; Raymakers, R; Richardson, PG; San-Miguel, J; Siegel, DS; Slaughter, A; Song, K; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Aebi, S; Driessen, C; Pabst, T; Renner, C; Zander, T | 1 |
| Chaleteix, C; Dougé, A; Lemal, R | 1 |
| Ahmadi, T; Arnulf, B; Chari, A; Chiu, C; Comenzo, R; Fay, JW; Ifthikharuddin, JJ; Kaufman, JL; Khokhar, NZ; Krishnan, A; Lentzsch, S; Lonial, S; Nottage, K; Suvannasankha, A; Wang, J; Weiss, BM | 1 |
| Baertsch, MA; Goldschmidt, H; Hillengass, J; Hundemer, M; Raab, MS | 1 |
| Algarín, EM; Corchete, LA; Díaz-Rodriguez, E; Díaz-Tejedor, A; Garayoa, M; González-Méndez, L; Gutiérrez, NC; Hernández-García, S; López-Iglesias, AA; Martín-Sánchez, M; Mateos, MV; Misiewicz-Krzeminska, I; Mogollón, P; Ocio, EM; Paíno, T; San-Segundo, L; Tunquist, B | 1 |
| Ailawadhi, S; Bergsagel, PL; Buadi, FK; Chanan-Khan, AA; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Hayman, SR; Kapoor, P; Kourelis, T; Kumar, S; Kyle, RA; Lacy, MQ; LaPlant, BR; Laumann, KM; Leung, N; Lin, Y; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK | 1 |
| Alarcón-Payer, C; Cabeza Barrera, J; de la Guardia, AMDVD; García Collado, CG; Jiménez Morales, A; Jurado Chacón, M; Martín-García, A; Ríos-Tamayo, R; Sánchez-Rodríguez, D | 1 |
| Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG | 1 |
| Auguston, B; Chan, KL; Dodds, A; Harrison, S; Ho, PJ; Kwok, F; Lee, C; Mollee, P; Morris, K; Quach, H; Ramakrishna, R; Ramanathan, S; Rowlings, P; Scott, A; Stark, R; Taper, J; Taylor, K; Tiley, C; Warburton, P; Watson, AM; Weber, N | 1 |
| Al, MJ; Albuquerque de Almeida, F; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Fayter, D; Kleijnen, J; Stirk, L; Wolff, R; Worthy, G | 1 |
| Hoy, SM | 1 |
| Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A | 1 |
| Berenson, JR; Bessudo, A; Cohen, A; Eshaghian, S; Flam, M; Klein, LM; Maluso, T; Nassir, Y; Rosen, PJ; Spektor, TM; Stampleman, L; Swift, RA; Vescio, R; Woliver, T | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Migkou, M; Ntanasis-Stathopoulos, I; Roussou, M; Terpos, E; Ziogas, DC | 1 |
| Belch, A; Diels, J; Ito, T; Oriol, A; Van Sanden, S; Vogel, M | 1 |
| Costello, C; Mikhael, JR | 1 |
| Sonneveld, P | 1 |
| Anderson, KC; Attal, M; Campana, F; Corzo, K; Hui, AM; Le-Guennec, S; Richardson, PG; Risse, ML | 1 |
| Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K | 1 |
| Araujo, C; Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Mathiot, C; Moreau, P; Pegourie, B; Perrot, A; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Wetterwald, M | 1 |
| Fuchida, SI; Hino, M; Iida, M; Imada, K; Ishikawa, J; Kamitsuji, Y; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsuda, M; Matsui, T; Matsumura, I; Matsumura-Kimoto, Y; Nakaya, A; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Wada, K; Yagi, H; Yokota, I | 1 |
| Aho, LS; Boulin, M; Caillot, D; Chretien, ML; Cransac-Miet, A; Favennec, C; Gueneau, P; Guy, J; Lafon, I | 1 |
| Belotti, A; Bertazzoni, P; Boccadoro, M; Bringhen, S; Cafro, AM; De Paoli, L; Fanin, R; Gaidano, G; Liberati, AM; Lombardo, A; Mina, R; Palumbo, A; Patriarca, F; Rossi, G; Sonneveld, P; Spada, S; Troia, R | 1 |
| Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S | 1 |
| Admojo, L; Darcy, PK; Davenport, AJ; Fairlie, DP; Gherardin, NA; Godfrey, DI; Harrison, SJ; Jenkins, MR; Kedzierska, K; Loh, L; McCluskey, J; Neeson, PJ; Prince, HM; Quach, H; Richardson, K; Ritchie, DS; Rogers, A; Uldrich, AP | 1 |
| Hillengass, J; Holstein, SA; McCarthy, PL | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Migkou, M; Terpos, E | 1 |
| Burslem, GM; Crews, CM; Cromm, PM; Jaime-Figueroa, S; Morgan, A; Ottis, P; Toure, M | 1 |
| Bernatowicz, P; Charlinski, G; Dmoszynska, A; Grzasko, N; Guzicka-Kazimierczak, R; Janczarski, M; Jurczyszyn, A; Lech-Maranda, E; Swiderska, A; Szczepaniak, A; Szeremet, A; Waszczuk-Gajda, A; Wichary, R | 1 |
| Garfall, AL; Hoteit, MA; Reed-Guy, L | 1 |
| Iwao, N; Kitahara, H; Koike, M; Komatsu, N; Ohta, Y; Watanabe, N | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Ahmed, R; Boise, LH; Chang, A; Kaufman, JL; Khan, MK; Lonial, S; Nasti, TH; Nooka, AK; Parashar, S | 1 |
| Borsi, E; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rocchi, S; Santacroce, B; Tacchetti, P; Terragna, C; Zamagni, E | 1 |
| Chao, NJ; Garrett, AH; Gasparetto, C; Green, MM; Kang, Y; Li, Z; Long, GD; McIntyre, JL; Rizzieri, DA; Sivaraj, D | 1 |
| Amatangelo, M; Bjorklund, C; Dimopoulos, MA; Flynt, E; Moreau, P; Ocio, EM; Peluso, T; Qian, X; Sternas, L; Thakurta, A; Towfic, F; Weisel, KC; Yu, X; Zaki, M | 1 |
| Tomlinson, R | 1 |
| Chu, TH; Jung, SH; Kim, HJ; Lakshmi, TJ; Lee, HJ; Lee, JJ; Park, HS; Vo, MC; Yang, S | 1 |
| Chehab, S; Gleason, C; Lonial, S; Nooka, AK; Panjic, EH | 1 |
| Mollee, P; Scott, AP | 1 |
| Allangba, O; Araujo, C; Attal, M; Belhadj, K; Benboubker, L; Berge, B; Brechignac, S; Chaleteix, C; Eisenmann, JC; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Garderet, L; Glaisner, S; Hulin, C; Jaccard, A; Jourdan, E; Karlin, L; Kuhnowski, F; Lafon, I; Leleu, X; Lenain, P; Loiseau, HA; Macro, M; Marit, G; Mathiot, C; Mohty, M; Moreau, P; Orsini-Piocelle, F; Pegourie, B; Perrot, A; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Voog, E; Wetterwald, M | 1 |
| Gourd, E | 1 |
| Jandial, A; Khadwal, A; Lad, D; Malhotra, P; Mishra, K; Prakash, G | 1 |
| Blanc, PD; Brown, JK; Callahan, EC; Elicker, B; Gajic, S; Ley, B | 1 |
| Blanchard, MJ; Fra-Fernández, S; Gorospe-Sarasúa, L; Velasco-Álvarez, D | 1 |
| Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Rafferty, B; Richardson, PG; Robbins, M; San-Miguel, J; Shelat, SG; Suzuki, K; Takezako, N | 1 |
| Burki, TK | 1 |
| Adamu, H; Arnall, JR; Bhutani, M; Mishkin, J; Usmani, SZ | 1 |
| Giralt, S; Seifter, E | 1 |
| Arnall, J; Atrash, S; Bhutani, M; Friend, R; Hamadeh, I; Hussain, MJ; Pineda-Roman, M; Robinson, MM; Symanowski, JT; Usmani, SZ; Voorhees, PM | 1 |
| Gong, CL; Liedtke, M; Studdert, AL | 1 |
| Nougawa, M; Oka, S; Shimazu, Y; Shiragami, H; Takeuchi, S | 1 |
| Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N | 1 |
| Boyer, A; Coleman, M; Forsberg, PA; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Perry, A; Rossi, AC; Tegnestam, L | 1 |
| Caballero García, A; Córdova Martínez, A; Fernández-Lázaro, CI; Fernández-Lázaro, D | 1 |
| Anderson, K; Bensinger, W; Campana, F; Dubin, F; Kanagavel, D; Karanes, C; Liu, Q; Mikhael, J; Raje, N; Richardson, P; Semiond, D; Usmani, SZ | 1 |
| Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S | 1 |
| Einsele, H; Nitschmann, S; Rasche, L | 1 |
| Benner, A; Besemer, B; Duerig, J; Goldschmidt, H; Haenel, M; Hose, D; Jauch, A; Kunz, C; Lindemann, HW; Mai, EK; Munder, M; Salwender, H; Scheid, C; Seckinger, A; Weisel, KC; Zago, M | 1 |
| Dingli, D; Mishra, AK | 1 |
| Adachi, H; Akiyama, M; Doki, N; Fujita, M; Igarashi, A; Inamoto, K; Kaito, S; Kakihana, K; Kishida, Y; Kobayashi, T; Konishi, T; Konuma, R; Kumagai, T; Nagata, A; Najima, Y; Ohashi, K; Sakamaki, H; Toya, T; Wada, A; Yamada, Y; Yoshifuji, K | 1 |
| Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM | 1 |
| Ali, Z; Anwer, F; Hassan, H; Hassan, SF; Iftikhar, A; Kamal, A; Lakhani, M; Mushtaq, A; Raychaudhuri, S; Razzaq, F; Safdar, A; Sagar, F; Zahid, U; Zar, MA | 1 |
| Kumar, SK | 1 |
| Boise, LH; Gleason, C; Gupta, VA; Heffner, LT; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK | 1 |
| Gay, F; Mina, R | 1 |
| Gütschow, M; Kehm, H; Krönke, J; Lindner, S; Mangold, M; Steinebach, C | 1 |
| Kim, GW; Kwon, SH; Lee, DH; Ryu, HW; Won, HR; Yeon, SK | 1 |
| Capalbo, SF; Cascavilla, N; Curci, P; Di Renzo, N; Falcone, AP; Fragasso, A; Guarini, A; Mazza, P; Mele, A; Mele, G; Miccolis, MR; Musto, P; Palazzo, G; Palumbo, G; Pastore, D; Pavone, V; Quinto, AM; Reddiconto, G; Rizzi, R; Specchia, G; Tarantini, G | 1 |
| Cavo, M | 2 |
| Berdeja, JG; Berenson, JR; Chang, YL; Klippel, Z; Lyons, RM; Niesvizky, R; Rifkin, RM; Shah, J; Stadtmauer, EA; Usmani, S | 1 |
| Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ | 1 |
| Furukawa, Y; Hagiwara, S; Hori, M; Iha, H; Izumi, T; Kikuchi, J; Koyama, D; Kuroda, Y; Suzuki, A; Toyama-Sorimachi, N; Yasui, H | 1 |
| Traynor, K | 1 |
| Lacy, MQ | 2 |
| Elkinson, S; McCormack, PL | 1 |
| Mahindra, A; Saini, N | 2 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Lokhorst, HM; van de Donk, NW | 1 |
| Lacy, MQ; Mark, TM; Richardson, PG | 1 |
| Forsberg, PA; Mark, TM | 1 |
| El-Amm, J; Tabbara, IA | 1 |
| Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A | 1 |
| Ishida, T | 1 |
| Bringhen, S; Gay, F; Mina, R; Troia, R | 1 |
| Lacy, MQ; McCurdy, AR | 1 |
| Alegre, A; Banos, A; Belch, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, M; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Lacy, M; Martinez-Lopez, J; Miguel, JS; Moreau, P; Oriol, A; Palumbo, A; Schey, S; Song, K; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Gras, J | 1 |
| Vij, R | 1 |
| Ahmann, G; Barlogie, B; Bergsagel, PL; Braggio, E; Bruins, LA; Champion, MD; Fonseca, R; Kortuem, KM; Kumar, S; Lacy, M; Laplant, B; Laumann, K; Mikhael, J; Rajkumar, SV; Schmidt, JE; Schuster, SR; Shi, CX; Stewart, AK; Zhu, YX | 1 |
| Mateos, MV; Ocio, EM; San Miguel, JF | 1 |
| Orlowski, RZ | 1 |
| Lonial, S | 1 |
| Abbasian, M; Breider, M; Carmel, G; Cathers, BE; Chen, G; Chopra, R; Daniel, TO; Gaidarova, S; Gandhi, AK; Jackson, P; Lopez-Girona, A; Mahmoudi, A; Mendy, D; Miller, K; Ren, Y; Rychak, E; Schafer, PH; Thakurta, A; Waldman, M; Wang, M | 1 |
| Motlló, C; Oriol, A | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Kyle, RA; Rajkumar, SV | 1 |
| Cavo, M; Davies, FE; Delforge, M; Dimopoulos, MA; Facon, T; Hansson, M; Leleu, X; Ludwig, H; Mateos, MV; Miguel, JF; Moreau, P; Morgan, GJ; Palumbo, A; Schey, SA; Sonneveld, P; Weisel, K; Zweegman, S | 1 |
| Scott, LJ | 1 |
| Coleman, M; Mark, TM; Niesvizky, R | 1 |
| Caraffa, P; Corvatta, L; Larocca, A; Leoni, P; Offidani, M; Palumbo, A; Pautasso, C | 1 |
| Engelhardt, M; Kleber, M; Reinhardt, H; Wäsch, R | 1 |
| Bergsagel, PL; Braggio, E; Bruins, LA; Champion, MD; Chang, XB; Fonseca, R; Jedlowski, P; Kortuem, KM; Lacy, M; Langlais, P; LaPlant, B; Laumann, K; Luo, M; Mikhael, J; Schmidt, JE; Shi, CX; Stewart, AK; Zhu, YX | 1 |
| Aerts, JL; Corthals, J; De Keersmaecker, B; Fostier, K; Heirman, C; Schots, R; Thielemans, K; Wilgenhof, S | 1 |
| Abramovitz, RB; Isola, LM; Jagannath, S; Parekh, S; Veluswamy, RR; Ward, SC; Yum, K | 1 |
| Kumar, A; Mishra, AK; Porwal, M; Verma, A | 1 |
| Chen, SE; Highsmith, KN; Horowitz, S | 1 |
| Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M | 1 |
| Cerase, A; Gozzetti, A | 1 |
| Cole, SW; Olin, JL; Summers, BB | 1 |
| Barlogie, B; Crowley, J; Hansen, E; Hoering, A; Panozzo, S; Petty, N; Qu, P; Steward, D; Stratton, K; Usmani, SZ; Van Rhee, F; Waheed, S; Yaccoby, S; Zhang, Q | 1 |
| Kumar, S; Singla, A | 1 |
| Gentili, S; Lonial, S | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Kuroda, J | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Akehurst, R; Delforge, M; Dhanasiri, S; Dimopoulos, MA; Facon, T; Jacques, C; Lee, D; Morgan, G; Offner, F; Oriol, A; Palumbo, A; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Amatya, R; Belch, A; Dimopoulos, MA; Jacques, C; Monzini, MS; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, KC; Yu, X; Zaki, M | 1 |
| Lonial, S; Usmani, SZ | 1 |
| Li, Y; Liu, L; Palmisano, M; Wang, X; Xu, Y; Zhou, S | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fuzibet, JG; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Lacotte, L; Legros, L; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Onraed, B; Pegourie, B; Petillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Tiab, M; Wetterwald, M | 1 |
| Babalola, O; Baird, P; Devoe, CE; Hoang, H; Jhaveri, KD; Leung, S; Wanchoo, R | 1 |
| Liu, G; Sheng, Z | 1 |
| Colson, K | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Ashjian, E; Redic, K | 1 |
| Adler, AI; Burke, MJ; George, E | 1 |
| Breider, M; Cooper, D; Couto, S; Das, R; Deng, Y; Dhodapkar, KM; Dhodapkar, MV; Hansel, D; Kocoglu, M; Koduru, S; Ren, Y; Sehgal, K; Seropian, S; Thakurta, A; Vasquez, J; Verma, R; Wang, M; Yao, X; Zhang, L | 1 |
| Sun, JJ; Yang, HL; Zhang, C; Zhou, J | 1 |
| Anderson, KC; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Mimura, N; Munshi, NC; Ohguchi, H; Richardson, PG; Tai, YT | 1 |
| Moreau, P; Touzeau, C | 2 |
| Anderson, KC | 1 |
| Bai, H; Ou, J; Wang, L; Zhang, S | 1 |
| Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Sternas, L; Teasdale, T; Weisel, KC; Yu, X; Zaki, MH | 1 |
| Mamdani, H; Modi, D; Vettese, T | 1 |
| Dimopoulos, MA; Palumbo, A; San-Miguel, J; Siegel, D; Sonneveld, P | 1 |
| Chen-Kiang, S; He, X; Huang, X; Jaffrey, SR; Jiang, X; Liu, Y; Xu, G; Zhou, Y | 1 |
| Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Hong, K; Ivanova, V; Jacques, C; Karlin, L; Knop, S; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Spencer, A; Sternas, L; Weisel, KC; Yu, X; Zaki, MH | 1 |
| Arnulf, B; Benboubker, L; Bories, C; Decaux, O; Demarquette, H; Fohrer, C; Fouquet, G; Guidez, S; Herbaux, C; Hulin, C; Karlin, L; Le Grand, C; Leleu, X; Macro, M; Prodhomme, C; Renaud, L; Roussel, M | 1 |
| Boise, LH; Kaufman, J; Lonial, S | 1 |
| Chou, T; Doerr, T; Iida, S; Iwasaki, H; Kurihara, M; Matsue, K; Midorikawa, S; Ogawa, Y; Sunami, K; Tobinai, K; Zaki, M | 1 |
| Acharya, C; Adrian, F; An, G; Anderson, KC; Dasilva, N; Feng, X; Jiang, H; Munshi, NC; Qiu, L; Richardson, P; Song, Z; Tai, YT; Wang, L; Yang, G; Zhong, M | 1 |
| Abonour, R; Bensinger, WI; Cohen, AD; Durie, BG; Gasparetto, C; Gomes, CL; Kaufman, JL; Lentzsch, S; Orlowski, RZ; Pascucci, N; Shah, JJ; Smith, DD; Stadtmauer, EA; Vogl, DT | 1 |
| Amatangelo, M; Bjorklund, CC; Breider, M; Chopra, R; Couto, S; Daniel, TO; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Klippel, A; Lu, L; Ning, Y; Ren, Y; Thakurta, AG; Wang, M | 1 |
| Anderson, KC; Chauhan, D; Das, DS; Ray, A; Richardson, P; Song, Y; Trikha, M | 1 |
| Ito, S | 1 |
| Cong, Z; Song, X; Wilson, K | 1 |
| Binder, G; Grigorian, M; Lee, C; Nolan, R; Rice, G | 1 |
| Al-Abed, Y; Allen, SL; An, X; Appiah-Kubi, AO; Blanc, L; Chan, KW; Didier, S; Dulmovits, BM; Gallagher, PG; Gould, M; Hale, J; He, M; Husain-Krautter, S; Lipton, JM; Liu, JM; Marambaud, P; Mohandas, N; Papoin, J; Singh, SA; Taylor, N; Vlachos, A | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benbouker, L; Brechiniac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Pegourie, B; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Wetterwald, M | 1 |
| Davies, FE; Jones, JR; Morgan, GJ; Pawlyn, C | 1 |
| Bjorklund, CC; Cathers, BE; Chopra, R; Daniel, TO; Gandhi, AK; Leisten, J; Lopez-Girona, A; Lu, L; Mendy, D; Miller, K; Narla, RK; Ning, Y; Orlowski, RZ; Raymon, HK; Rychak, E; Shi, T; Thakurta, A | 1 |
| Alsina, M; Baz, RC; Chari, A; Cho, HJ; Jagannath, S; Lau, K; Lin, HY; Mahindra, A; Martin, TG; Nardelli, LA; Shain, KH; Sullivan, DM; Wolf, JL; Zhao, X | 1 |
| Bolomsky, A; Ludwig, H; Schlangen, K; Schreiner, W; Zojer, N | 1 |
| Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W | 1 |
| Anderson, KC; Attal, M; Avet-Loiseau, H; Bladé, J; Caers, J; Chng, WJ; Durie, BG; Einsele, H; Goldschmidt, H; Hillengass, J; Kyle, RA; Lonial, S; Mateos, MV; Moreau, P; Orlowski, R; Palumbo, A; San Miguel, J; Siegel, D; Sonneveld, P; Usmani, S; van de Donk, NW | 1 |
| Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM | 1 |
| Jung, CK; Jung, Y; Kang, SW; Kim, BG; Kim, TH; Lee, SE; Lim, JY; Min, CK; Park, E; Park, J; Won, KA | 1 |
| Biran, N; Duma, N; Richter, J; Siegel, D; Vesole, DH | 1 |
| Broijl, A; Sonneveld, P | 1 |
| Alegre, A; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Hong, K; Ivanova, V; Jacques, C; Karlin, L; Knop, S; Lacy, MQ; Martinez-Lopez, J; Moreau, P; Oriol, A; San Miguel, J; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, MH | 1 |
| Anderson, KC; Chauhan, D; Das, A; Das, DS; Oronsky, B; Ray, A; Richardson, P; Scicinski, J; Song, Y; Tian, Z | 1 |
| Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U | 1 |
| Dimopoulos, MA; Gibson, CJ; Hong, K; Moreau, P; Saunders, O; Song, KW; Sternas, LA; Weisel, KC; Zaki, MH | 1 |
| Anttila, P; Blanchard, MJ; Cafro, AM; Cavo, M; Corradini, P; de Arriba, F; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Doyen, C; Goldschmidt, H; Hansson, M; Herring, J; Kaiser, M; Knop, S; Miller, N; Moreau, P; Morgan, G; Ocio, EM; Oriol, A; Palumbo, A; Peluso, T; Petrini, M; Raymakers, R; Röllig, C; San-Miguel, J; Simcock, M; Sternas, L; Vacca, A; Weisel, KC; Zaki, MH | 1 |
| Lonial, S; Nooka, AK | 1 |
| Baz, R; Cavo, M; Delforge, M; Dimopoulos, MA; Goldschmidt, H; Hong, K; Jagannath, S; Moreau, P; Palumbo, A; Richardson, P; San Miguel, JF; Siegel, DS; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, M | 1 |
| Body, S; Bourgeais, J; Bustany, S; Gouilleux, F; Hérault, O; Sola, B; Tchakarska, G | 1 |
| Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F | 1 |
| Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM | 1 |
| Boyd, KD; Davies, FE; Dearden, CE; Kaiser, MF; Mohammed, K; Morgan, GJ; Pawlyn, C; Sriskandarajah, P | 1 |
| Fan, L; Hu, C; Ma, X; Ran, X; Yu, H; Zou, Y | 1 |
| Krönke, J; Lindner, S | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 1 |
| Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
| Abe, M; Aihara, K; Amachi, R; Bat-Erdene, A; Cui, Q; Endo, I; Fujii, S; Harada, T; Iwasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Sogabe, K; Teramachi, J; Yoshida, S | 1 |
| Boccadoro, M; Bonello, F; Larocca, A; Salvini, M | 1 |
| Hangaishi, A; Hirao, M; Iizuka, H; Kida, M; Usuki, K | 1 |
| Buclin, T; Chtioui, H; Dao, K; Figg, WD; Kissling, S; Lu, Y; Peer, CJ; Pruijm, M | 1 |
| Conticello, C; Di Raimondo, F | 1 |
| Asproni, R; Latte, G; Monne, M; Murineddu, M; Palmas, A; Piras, G; Stradoni, R; Uras, A | 1 |
| Ancora, F; Calafiore, V; Consoli, ML; Conticello, C; Di Raimondo, F; La Fauci, A; Parisi, M; Romano, A | 1 |
| Abouzaid, S; Chen, CC; Hussein, M; McGuiness, CB; Parikh, K; Purnomo, L; Wade, RL | 1 |
| Lentzsch, S; Raza, S; Safyan, RA | 1 |
| Holstein, SA; McCarthy, PL | 1 |
| Benjamin, R; Cerner, A; Cheesman, S; D'sa, S; Jenner, M; Maciocia, N; Maciocia, P; Melville, A; Popat, R; Rabin, N; Ramasamy, K; Rismani, A; Schey, S; Sharpley, F; Streetly, M; Yong, K | 1 |
| Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Wiernik, PH | 1 |
| Jagannath, S | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Stewart, AK | 1 |
| Brady, HA; Chan, KW; Escoubet-Lozach, L; Gandhi, AK; Jensen-Pergakes, K; Lin, IL; Muller, GW; Schafer, PH; Verhelle, D; Worland, PJ | 1 |
| Hussein, M; Srkalovic, G | 1 |
| Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P | 1 |
| Stewart, AK | 2 |
| Lacy, MQ; Rajkumar, SV | 1 |
| Gahrton, G | 1 |
| Anderson, KC; Bandi, M; Calabrese, E; Cirstea, D; Fabre, C; Görgün, G; Hideshima, T; Hu, Y; Mimura, N; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Soydan, E; Tai, YT | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Schots, R | 1 |
| Buadi, F; Dispenzieri, A; Gertz, M; Hayman, S; Kumar, S; Kyle, RA; Lacy, MQ; Larson, D; Mikhael, J; Rajkumar, SV; Roy, V; Short, KD | 1 |
| Galson, DL; Lentzsch, S; Li, S; Mapara, M; Monaghan, SA; Ouyang, H; Pal, R; Schafer, P | 1 |
| Ramasamy, K; Schey, S | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Geyer, HL; Lacy, MQ; Leslie, KO; Mikhael, JR; Stewart, K; Viggiano, RW; Witzig, TE | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Hata, H | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, M; Hayman, S; Kumar, SK; Lacy, M; Mikhael, J; Rajkumar, SV; Sinha, S | 1 |
| Cannavò, A; Castelli, R; Conforti, F; Cortelezzi, A; Grava, G | 1 |
| Iida, S | 1 |
| Niesvizky, R | 1 |
| Lentzsch, S; Pan, B | 1 |
| Dalto, S; Montefusco, V; Mussetti, A | 1 |
| Gertz, MA | 1 |
| Kortuem, KM; Stewart, AK; Zhu, YX | 1 |
| Arima, N; Kawada, H | 1 |
| Agnelli, L; Bolzoni, M; Bonomini, S; Giuliani, N; Guasco, D; Neri, A; Rizzoli, V; Storti, P; Todoerti, K; Toscani, D | 1 |
| Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C | 1 |
| Bartlett, JB; Dalgleish, AG; Dredge, K | 1 |
| Anderson, K; Richardson, P | 1 |
| Ashan, G; Bartlett, JB; Clarke, IA; Dalgleish, AG; Fields, P; Knight, RD; Schey, SA; Streetly, M | 1 |
| Hunt, BJ; Jones, R; Parmar, K; Schey, S; Streetly, M; Zeldis, J | 1 |
| Knight, R | 1 |
| Child, JA; Russell, N; Schey, S; Sonneveld, P | 1 |
| Crane, E; List, A | 1 |
| Anderson, G; Anderson, J; Donnenberg, A; Donnenberg, V; Ghobrial, I; Gries, M; Honjo, T; Kurihara, N; Lentzsch, S; Mapara, MY; Roodman, D; Stirling, D | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Hussein, MA; Srkalovic, JG; Suppiah, R | 1 |
| Brown, KA; Macey, MG; McCarthy, DA; Schey, SA; Streetly, M | 1 |
| Ribatti, D; Vacca, A | 1 |
| Daniel, Y; Gyertson, K; Kazmi, M; Schey, SA; Streetly, MJ; Zeldis, JB | 1 |
89 review(s) available for pomalidomide and Kahler Disease
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Recurrence | 2023 |
Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis | 2023 |
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
Isatuximab: First Approval.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Approval; Humans; Injections, Intravenous; Multiple Myeloma; Thalidomide; United States | 2020 |
Sequencing multiple myeloma therapies with and after antibody therapies.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2020 |
An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2021 |
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Design; Humans; Immunologic Factors; Multiple Myeloma; Survival Rate; Thalidomide | 2017 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Technology Assessment, Biomedical; Thalidomide | 2018 |
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Multiple Myeloma; Recurrence; Thalidomide; Treatment Failure | 2017 |
Management of multiple myeloma in the relapsed/refractory patient.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Immunomodulatory effects of CD38-targeting antibodies.
Topics: Adenosine; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes, Regulatory; B7-H1 Antigen; Humans; Immunologic Factors; Lenalidomide; Membrane Glycoproteins; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Thalidomide | 2018 |
Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Topics: Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Infusions, Intravenous; Membrane Glycoproteins; Molecular Targeted Therapy; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |
Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Back Pain; Female; Humans; Ibuprofen; Immunologic Factors; Lumbar Vertebrae; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Thalidomide; Thoracic Vertebrae; Tomography, X-Ray Computed | 2018 |
[Immunomodulator drugs for the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2019 |
Pomalidomide: first global approval.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Approval; Graft vs Host Disease; Humans; Multiple Myeloma; Thalidomide | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2013 |
Emerging therapies in multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Signal Transduction; Thalidomide | 2015 |
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunologic Factors; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2013 |
Pomalidomide.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Immunomodulation; Multiple Myeloma; Thalidomide | 2013 |
Pomalidomide for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclinical; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Thalidomide; United States; United States Food and Drug Administration | 2013 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrroles; Recurrence; Thalidomide; Treatment Outcome | 2013 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
[New drugs in the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Synergism; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Protease Inhibitors; Protein Kinase Inhibitors; Thalidomide | 2014 |
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
Topics: Age Factors; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Humans; Immunologic Factors; Infections; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Quality of Life; Thalidomide; Venous Thromboembolism | 2014 |
Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2014 |
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2014 |
Pomalidomide.
Topics: Animals; Antineoplastic Agents; Humans; Multiple Myeloma; Thalidomide | 2014 |
Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Topics: Animals; Clinical Trials as Topic; Female; Humans; Immunologic Factors; Male; Multiple Myeloma; Thalidomide | 2014 |
Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Survival Rate; Thalidomide; Treatment Outcome | 2014 |
Novel agents in CNS myeloma treatment.
Topics: Animals; Blood-Brain Barrier; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide for the management of refractory multiple myeloma.
Topics: Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2014 |
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; TOR Serine-Threonine Kinases | 2011 |
Relapsed and refractory multiple myeloma: new therapeutic strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Current status of clinical trials of novel agents for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Approval; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Pyrroles; Thalidomide; Vorinostat | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease Progression; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2014 |
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2016 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Neoplasm Recurrence, Local; Pharmacists; Professional Role; Proteasome Inhibitors; Thalidomide; Treatment Outcome | 2016 |
Pomalidomide (Pomalyst) for multiple myeloma.
Topics: Animals; Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2015 |
Multiple myeloma: from front-line to relapsed therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Humans; Methotrexate; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Randomized Controlled Trials as Topic; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Vincristine | 2015 |
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Risk Factors; Thalidomide | 2015 |
[Pomalidomide for multiple myeloma].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Molecular Conformation; Multiple Myeloma; Structure-Activity Relationship; Thalidomide | 2015 |
The safety of pomalidomide for the treatment of multiple myeloma.
Topics: Clinical Trials as Topic; Cohort Studies; Humans; Immunologic Factors; Meta-Analysis as Topic; Multiple Myeloma; Observational Studies as Topic; Randomized Controlled Trials as Topic; Safety; Thalidomide | 2016 |
Treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Palliative Care; Plasma Cells; Precision Medicine; Proteasome Inhibitors; Recurrence; Thalidomide | 2016 |
New Targets and New Agents in High-Risk Multiple Myeloma.
Topics: Cancer Vaccines; GTP Phosphohydrolases; Humans; Immunomodulation; Membrane Proteins; Molecular Targeted Therapy; Multiple Myeloma; Mutation; Precision Medicine; Proteasome Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Risk Assessment; Thalidomide | 2016 |
Pomalidomide in the management of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2016 |
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Prospective Studies; Salvage Therapy; Thalidomide | 2017 |
The molecular mechanism of thalidomide analogs in hematologic malignancies.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Protein Binding; Proteolysis; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Survival Rate; Thalidomide | 2017 |
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Quality of Life; Thalidomide; Venous Thromboembolism | 2017 |
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Oligopeptides; Thalidomide; Xenograft Model Antitumor Assays | 2017 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Topics: Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Topics: Cytokines; Humans; Immunologic Factors; Multiple Myeloma; Neovascularization, Pathologic; Primary Myelofibrosis; Signal Transduction; Thalidomide | 2010 |
Progress in allogeneic transplantation for multiple myeloma.
Topics: Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Killer Cells, Natural; Lymphocyte Transfusion; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2010 |
New immunomodulatory drugs in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Thalidomide; Treatment Outcome | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
Pomalidomide therapy for myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2011 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat | 2011 |
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Topics: Animals; Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide; Tumor Microenvironment | 2012 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
Novel therapies in monoclonal gammopathies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2012 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Gene Expression; Humans; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Novel immunomodulatory compounds in multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Molecular Structure; Multiple Myeloma; Thalidomide | 2013 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
IMiDs: a novel class of immunomodulators.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2005 |
Future directions in multiple myeloma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Evaluation; Forecasting; Humans; Interferon-gamma; Interleukin-2; Multiple Myeloma; Remission Induction; Thalidomide | 2005 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide | 2005 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
88 trial(s) available for pomalidomide and Kahler Disease
| Article | Year |
|---|---|
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2021 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2022 |
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Progression-Free Survival; Sulfonamides; Thalidomide | 2021 |
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2021 |
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2021 |
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2022 |
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide; Treatment Outcome | 2022 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide | 2022 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Thalidomide | 2022 |
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide | 2022 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Thalidomide | 2022 |
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2022 |
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukopenia; Multiple Myeloma; Prospective Studies; Thalidomide | 2022 |
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Survival Analysis | 2023 |
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Treatment Outcome | 2023 |
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Thalidomide | 2023 |
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma | 2023 |
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Positron Emission Tomography Computed Tomography; Transplantation, Autologous | 2023 |
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Topics: Humans; Lenalidomide; Multiomics; Multiple Myeloma; Proteomics; Tumor Microenvironment | 2023 |
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial.
Topics: Dexamethasone; Humans; Multiple Myeloma; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2023 |
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia | 2023 |
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2020 |
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Thalidomide | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Dexamethasone; Europe; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; North America; Progression-Free Survival; Thalidomide; Treatment Outcome | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2020 |
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide; Treatment Outcome | 2020 |
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Stroke; Thalidomide; Thrombophilia; Venous Thromboembolism; Venous Thrombosis | 2020 |
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2020 |
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Renal Insufficiency; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kinesins; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Orosomucoid; Spain; Thalidomide; Thiadiazoles; Treatment Outcome | 2021 |
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Multiple Myeloma; Thalidomide; Tumor Microenvironment | 2020 |
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Thalidomide | 2021 |
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Cell Maturation Antigen; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Receptors, Chimeric Antigen; Survival Rate; Thalidomide | 2021 |
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Survival Rate; Thalidomide | 2021 |
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Dexamethasone; Disease-Free Survival; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2021 |
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Patient Safety; Salvage Therapy; Thalidomide; Treatment Outcome | 2021 |
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; Proportional Hazards Models; Thalidomide | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Prospective Studies; Recurrence; Thalidomide | 2021 |
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Multiple Myeloma; Neutropenia; Thalidomide | 2021 |
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Frail Elderly; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2021 |
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; B7-H1 Antigen; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Multiple Myeloma; Receptors, Antigen, T-Cell; Sequence Analysis, RNA; Thalidomide; Tumor Microenvironment | 2021 |
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Demography; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pneumonia; Thalidomide; Treatment Outcome | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2018 |
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Oligopeptides; Prognosis; Survival Rate; Thalidomide | 2018 |
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.
Topics: Female; Humans; Immunity, Cellular; Interferon-gamma; Killer Cells, Natural; Lenalidomide; Male; Mucosal-Associated Invariant T Cells; Multiple Myeloma; Neoplasm Proteins; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2018 |
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Immunologic Factors; Infections; Male; Middle Aged; Multiple Myeloma; Neutropenia; Thalidomide | 2018 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome | 2019 |
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2019 |
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Progression-Free Survival; Thalidomide | 2019 |
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Multiple Myeloma; Myocarditis; Progression-Free Survival; Proportional Hazards Models; Recurrence; Stevens-Johnson Syndrome; Survival Rate; Thalidomide; Treatment Outcome | 2019 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2013 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Cross-Over Studies; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Multiple Myeloma; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2015 |
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Thalidomide | 2015 |
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Deletion; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide; Translocation, Genetic | 2015 |
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Topics: Angiogenesis Inhibitors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Killer Cells, Natural; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes; Thalidomide; Tumor Microenvironment | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2015 |
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Thalidomide; Treatment Outcome | 2015 |
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Asian People; Dexamethasone; Disease-Free Survival; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Thalidomide | 2015 |
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Pneumonia; Pulmonary Embolism; Recurrence; Thalidomide; Time Factors | 2015 |
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2016 |
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lactones; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrroles; Recurrence; Thalidomide | 2016 |
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2009 |
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Incidence; Multiple Myeloma; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome | 2011 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Cytokines; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2004 |
The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.
Topics: Adult; Aged; Apoptosis; Blood Platelets; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Neutropenia; Neutrophils; Receptors, IgG; Thalidomide | 2006 |
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lymphocyte Subsets; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neutropenia; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
212 other study(ies) available for pomalidomide and Kahler Disease
| Article | Year |
|---|---|
Protein Degradation via CRL4
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Chemistry Techniques, Synthetic; Drug Evaluation, Preclinical; Humans; Ikaros Transcription Factor; Molecular Docking Simulation; Multiple Myeloma; Peptide Hydrolases; Peptide Termination Factors; Phthalimides; Piperidones; Proteolysis; Quantitative Structure-Activity Relationship; Ubiquitin-Protein Ligases | 2018 |
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Crystallography, X-Ray; DNA-Binding Proteins; Fluorescence Resonance Energy Transfer; Heterocyclic Compounds, 4 or More Rings; Humans; Ikaros Transcription Factor; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Phthalimides; Piperidones; Protein Binding; Proteolysis; Ubiquitin-Protein Ligases | 2018 |
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Development; HeLa Cells; Hep G2 Cells; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; MCF-7 Cells; Multiple Myeloma | 2019 |
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitory Concentration 50; Mice; Multiple Myeloma; Recurrence; Stereoisomerism; Treatment Failure; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2020 |
Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis.
Topics: Angiogenesis Inhibitors; Apoptosis; Caffeic Acids; Cell Line, Tumor; Down-Regulation; Genes, myc; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Phenylethyl Alcohol; Sp1 Transcription Factor; Structure-Activity Relationship | 2020 |
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Burkitt Lymphoma; Carcinoma, Lewis Lung; Cell Division; Growth Inhibitors; Humans; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Multiple Myeloma; Neovascularization, Physiologic; Thalidomide; Xenograft Model Antitumor Assays | 2002 |
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thalidomide | 2021 |
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Progression-Free Survival; Prospective Studies; Thalidomide | 2022 |
Isatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Multiple Myeloma; Renal Dialysis | 2021 |
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Knockout Techniques; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Nuclear Receptor Co-Repressor 2; Proto-Oncogene Proteins c-myc; Thalidomide; Up-Regulation | 2021 |
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Topics: Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2022 |
Pomalidomide-based therapy for extramedullary multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Retrospective Studies; Thalidomide; Treatment Outcome | 2022 |
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Patient Reported Outcome Measures; Quality of Life; Thalidomide | 2022 |
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2022 |
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2022 |
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2022 |
Successful Treatment of the TEMPI Syndrome with Pomalidomide Plus Dexamethasone Followed by Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Proteasome Inhibitors; Thalidomide; Transplantation, Autologous | 2022 |
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pandemics; Retrospective Studies; Thalidomide; United Kingdom | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Standard of Care; Thalidomide | 2022 |
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hungary; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Treatment Outcome | 2022 |
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Czech Republic; Dexamethasone; Humans; Multiple Myeloma; Routinely Collected Health Data | 2022 |
Pomalidomide-induced lung injury: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dyspnea; Humans; Lung Injury; Male; Multiple Myeloma | 2023 |
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Topics: Aged; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2023 |
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Frailty; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; United Kingdom | 2023 |
Pomalidomide combinations are a safe and effective option after daratumumab failure.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Salvage Therapy; Thalidomide; Treatment Failure | 2023 |
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Salvage Therapy | 2023 |
[The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2023 |
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; POEMS Syndrome; Thalidomide | 2023 |
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Assessment; Transplantation, Autologous | 2023 |
[Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
[The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].
Topics: Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2023 |
[Bendamustine combined with pomalidomide and dexamethasone in relapsed multiple myeloma with extramedullary disease: a multicenter study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Middle Aged; Multiple Myeloma; Prospective Studies | 2023 |
Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series.
Topics: Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2019 |
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Topics: Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Recurrence; Remission Induction; Thalidomide; Transplantation, Homologous | 2019 |
Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.
Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Failure | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Leukocytes, Mononuclear; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2020 |
Incorporating isatuximab in the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2019 |
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Dosage Calculations; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Progression-Free Survival; Thalidomide | 2019 |
Pomalidomide desensitization for hypersensitivity: A case report.
Topics: Aged; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide; Urticaria | 2020 |
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Piperacillin, Tazobactam Drug Combination; Pyoderma Gangrenosum; Thalidomide | 2020 |
[Effect of Pomalidomide on Activity of Myeloma Cell Line MM1.S and Expression of CRBN].
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases | 2019 |
Daratumumab-associated hemophagocytic lymphohistiocytosis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphohistiocytosis, Hemophagocytic; Middle Aged; Multiple Myeloma; Thalidomide | 2020 |
[Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2020 |
Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Genome-Wide Association Study; Humans; Multiple Myeloma; Neoplasm Proteins; Phenylurea Compounds; Thalidomide; Ubiquitin-Protein Ligases | 2020 |
Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2020 |
Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration.
Topics: Aged; Clinical Deterioration; Dexamethasone; Female; Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm Recurrence, Local; Parietal Lobe; Thalidomide; White Matter | 2020 |
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2020 |
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Topics: Cell Line, Tumor; Chemokine CCL5; Coculture Techniques; Humans; Interferon Regulatory Factors; Intramolecular Oxidoreductases; Lenalidomide; Macrophage Migration-Inhibitory Factors; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Thalidomide | 2020 |
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2021 |
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pneumonia; Progression-Free Survival; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Treatment Outcome | 2020 |
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cell Proliferation; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Dendritic Cells; Drug Evaluation, Preclinical; Female; Immune Checkpoint Inhibitors; Immunosuppressive Agents; Immunotherapy; Mice; Mice, Inbred BALB C; Multiple Myeloma; Spleen; T-Lymphocytes, Cytotoxic; Thalidomide; Vaccination | 2021 |
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2021 |
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Treatment Outcome | 2019 |
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Treatment Outcome | 2019 |
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Topics: Animals; Humans; Immunomodulation; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Pharmaceutical Preparations; Thalidomide | 2020 |
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Proliferation; Dexamethasone; Female; Humans; Immunomodulation; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes, Regulatory; Thalidomide | 2020 |
ARID2 is a pomalidomide-dependent CRL4
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Lenalidomide; Multiple Myeloma; Mutation; Protein Binding; Proteolysis; RNA, Messenger; RNA, Small Interfering; Thalidomide; Time Factors; Transcription Factors; Ubiquitin-Protein Ligases; Ubiquitination | 2020 |
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Body Weight; Case-Control Studies; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Histocompatibility Antigens Class I; Humans; Male; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Pharmaceutical Preparations; Receptors, Fc; Recurrence; Thalidomide; Time Factors | 2020 |
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Transplantation, Autologous | 2021 |
Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Survival; Female; HEK293 Cells; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Multiple Myeloma; Point Mutation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hypophosphatemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Thalidomide | 2021 |
Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide.
Topics: Adrenergic beta-Antagonists; Humans; Multiple Myeloma; Prognosis; Thalidomide; Treatment Outcome | 2021 |
Pomalidomide and dexamethasone in myelomatous pleural effusion.
Topics: Dexamethasone; Drainage; Dyspnea; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Pleural Effusion, Malignant; Radiography, Thoracic; Thalidomide; Thoracentesis; Treatment Outcome | 2020 |
Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity.
Topics: Animals; Cell Proliferation; Drug Design; Female; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Sulfides; Thalidomide; Xenograft Model Antitumor Assays | 2021 |
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Drug Resistance, Neoplasm; Genetic Variation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Lenalidomide; Mesenchymal Stem Cells; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Thalidomide; United States | 2021 |
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Oligopeptides; Progression-Free Survival; Thalidomide | 2021 |
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; SOXB1 Transcription Factors; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma-Experience From a Tertiary Care Cancer Center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Retrospective Studies; Tertiary Healthcare; Thalidomide | 2021 |
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Topics: Black or African American; Humans; Hyperpigmentation; Immunologic Factors; Incidence; Lenalidomide; Multiple Myeloma; Organ Specificity; Retrospective Studies; Thalidomide | 2021 |
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Management; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2021 |
Plasma cell dedifferentiation in refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Dedifferentiation; Dexamethasone; Flow Cytometry; Humans; Immunophenotyping; Male; Multiple Myeloma; Mutation; Myelodysplastic Syndromes; Paraproteinemias; Plasma Cells; Thalidomide; Treatment Failure; Tumor Suppressor Protein p53 | 2021 |
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Chromosomes, Human, Pair 1; Clinical Trials, Phase III as Topic; Dexamethasone; Febrile Neutropenia; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia; Randomized Controlled Trials as Topic; Recurrence; Risk; Salvage Therapy; Thalidomide; Trisomy | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Retrospective Studies; Thalidomide | 2021 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Germany; Health Surveys; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous | 2017 |
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dendritic Cells; Disease Models, Animal; Drug Synergism; Humans; Mice; Multiple Myeloma; Neoplastic Stem Cells; Osteoblasts; Osteoclasts; Proteasome Inhibitors; Recombinant Fusion Proteins; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Time Factors | 2017 |
Spotlight on pomalidomide: could less be more?
Topics: Adjuvants, Immunologic; Dexamethasone; Drug Administration Schedule; Drug Costs; Humans; Multiple Myeloma; Survival Analysis; Thalidomide | 2017 |
[Pomalidomide for multiple myeloma].
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2017 |
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Humans; Multiple Myeloma; Survival Analysis; Thalidomide | 2018 |
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cells, Cultured; Dexamethasone; Drug Synergism; Humans; Kinesins; Mice; Multiple Myeloma; Thalidomide; Thiadiazoles; Treatment Outcome | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Humans; Models, Economic; Multiple Myeloma; Oligopeptides; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States | 2017 |
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromatin; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Expression Profiling; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Pyridones; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2018 |
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Therapy sequencing strategies in multiple myeloma: who, what and why?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Thalidomide | 2018 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom | 2018 |
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Thalidomide | 2018 |
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Neutropenia; Recurrence; Registries; Retrospective Studies; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Odds Ratio; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Embolism; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2019 |
Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase.
Topics: Dexamethasone; Humans; Multiple Myeloma; Thalidomide; Ubiquitin; Ubiquitin-Protein Ligases | 2018 |
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Topics: Adaptor Proteins, Signal Transducing; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Structure-Activity Relationship; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Poland; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Multiple Myeloma; Recovery of Function; Thalidomide; Treatment Outcome | 2018 |
Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunologic Factors; Multiple Myeloma; Recurrence; Thalidomide | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Dexamethasone; Female; Humans; Immunotherapy; Middle Aged; Multiple Myeloma; Myocarditis; Nivolumab; Off-Label Use; Thalidomide | 2018 |
Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2018 |
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computational Biology; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Immunologic Factors; Male; Middle Aged; Molecular Sequence Annotation; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2019 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Cytokines; Dendritic Cells; Dexamethasone; Female; Immunization; Immunomodulation; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Macrophages; Mice; Multiple Myeloma; Myeloid-Derived Suppressor Cells; T-Lymphocyte Subsets; Thalidomide; Tumor Microenvironment | 2018 |
Pomalidomide - Author Reply.
Topics: Australia; Humans; Multiple Myeloma; Neoplasms, Plasma Cell; Thalidomide | 2019 |
Combination therapy for first relapse of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dexamethasone; Disease Progression; Humans; Multicenter Studies as Topic; Multiple Myeloma; Recurrence; Remission Induction; Stem Cell Transplantation; Thalidomide; Time Factors; Treatment Outcome | 2018 |
Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Humans; Multiple Myeloma; Thalidomide | 2019 |
Pulmonary toxicity associated with pomalidomide.
Topics: Antineoplastic Agents; Humans; Lung; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pulmonary Fibrosis; Thalidomide; Tomography, X-Ray Computed | 2018 |
Extramedullary Multiple Myeloma With Pleural Involvement: A Rare Clinical Entity.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drainage; Humans; Male; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pleural Effusion, Malignant; Pleurodesis; Radiotherapy, Adjuvant; Remission Induction; Talc; Thalidomide | 2019 |
Elotuzumab in multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Multiple Myeloma; Progression-Free Survival; Randomized Controlled Trials as Topic; Thalidomide; Time Factors | 2018 |
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Dexamethasone; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2019 |
Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Multiple Myeloma; Quality of Life; Quality-Adjusted Life Years; Recurrence; Survival Analysis; Thalidomide | 2019 |
[Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2018 |
[Pomalidomide].
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Thalidomide | 2016 |
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multimodal Imaging; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Soft Tissue Neoplasms; Thalidomide | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluation; Drug Substitution; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Protease Inhibitors; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2019 |
[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2019 |
Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Bortezomib; Cell Line, Tumor; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-6; Metformin; Multiple Myeloma; Phenformin; Plasma Cells; Receptors, Interleukin-6; Sequence Analysis, RNA; Signal Transduction; Syndecan-1; Thalidomide | 2019 |
Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Topics: Adult; Benzylamines; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome, Human; Humans; Ikaros Transcription Factor; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-myc; Recurrence; Survival Analysis; Thalidomide; Translocation, Genetic; Whole Genome Sequencing | 2019 |
Recycling therapies for myeloma: The need for prospective trials.
Topics: Antibodies, Monoclonal; Dexamethasone; Humans; Multiple Myeloma; Prospective Studies; Thalidomide; Treatment Outcome | 2019 |
Redefining the treatment paradigm for multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Topics: Adaptor Proteins, Signal Transducing; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line, Tumor; Cell Survival; Humans; Leupeptins; Multiple Myeloma; Protein Multimerization; Proteolysis; Proton Magnetic Resonance Spectroscopy; Thalidomide; Ubiquitin-Protein Ligases | 2019 |
HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Topics: Apoptosis; Benzene Derivatives; Cell Proliferation; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured | 2019 |
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2019 |
Facing lenalidomide-refractory myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Research Design; Retreatment; Thalidomide | 2019 |
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Humans; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Xenograft Model Antitumor Assays | 2020 |
Pomalidomide approved for multiple myeloma.
Topics: Antineoplastic Agents; Drug Approval; Drug Labeling; Humans; Multiple Myeloma; Thalidomide; United States | 2013 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2013 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
[II. Immunomodulation for multiple myeloma].
Topics: Bone Marrow Transplantation; Glucosides; Humans; Immunomodulation; Lenalidomide; Multiple Myeloma; Phenols; Thalidomide | 2013 |
Haematological cancer: a step before the next leap?
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Multiple Myeloma; Prognosis; Salvage Therapy; Thalidomide | 2013 |
The clinical significance of cereblon expression in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Peptide Hydrolases; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2014 |
"A fortuitous combination of circumstances".
Topics: Cyclophosphamide; Female; Humans; Male; Multiple Myeloma; Prednisone; Thalidomide | 2013 |
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
Topics: Adaptor Proteins, Signal Transducing; Alternative Splicing; Antibodies, Monoclonal; Antibody Specificity; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Peptide Hydrolases; RNA Isoforms; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
An overview of the progress in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Drug Therapy, Combination; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide | 2014 |
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; alpha Karyopherins; Anti-Inflammatory Agents; Biomarkers, Tumor; Blotting, Western; Carrier Proteins; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Flow Cytometry; Follow-Up Studies; Humans; Ikaros Transcription Factor; Immunologic Factors; Immunoprecipitation; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Prognosis; Prospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2014 |
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dendritic Cells; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2014 |
Adverse drug reaction: pomalidomide-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Thalidomide | 2014 |
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Transplantation; Nerve Tissue Proteins; Plasmacytoma; Signal Transduction; Thalidomide; Trans-Activators | 2015 |
Population pharmacokinetics of pomalidomide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Immunologic Factors; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Multiple Myeloma; Renal Insufficiency; Sex Factors; Thalidomide | 2015 |
A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Levofloxacin; Multiple Myeloma; Thalidomide | 2016 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Pooled analysis of pomalidomide for treating patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Meta-Analysis as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Thalidomide | 2015 |
Pomalidomide. A last-line treatment option for multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Immunomodulation; In Vitro Techniques; Lenalidomide; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Thalidomide; Transfection; Vorinostat | 2015 |
Multiple myeloma: new uses for available agents, excitement for the future.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Proteasome Inhibitors; Thalidomide | 2015 |
[Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266].
Topics: Cell Line, Tumor; Coculture Techniques; Enzyme-Linked Immunosorbent Assay; Humans; Multiple Myeloma; Recoverin; T-Lymphocytes; Thalidomide | 2015 |
Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
Topics: Aged; Biopsy; Bronchoalveolar Lavage Fluid; Diagnosis, Differential; Humans; Immunologic Factors; Lung Diseases, Interstitial; Male; Multiple Myeloma; Radiography; Thalidomide | 2015 |
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; HEK293 Cells; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
How I treat high-risk myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2015 |
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
Topics: Actins; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Humanized; Apoptosis; Genes, p53; Humans; Lysosomes; Membrane Glycoproteins; Membrane Microdomains; Multiple Myeloma; Reactive Oxygen Species; Thalidomide | 2016 |
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Flow Cytometry; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunoblotting; Immunohistochemistry; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; Signal Transduction; Thalidomide | 2015 |
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lactones; Mice, SCID; Multiple Myeloma; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrroles; RNA, Small Interfering; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2015 |
[Novel agents in multiple myeloma treatment].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Oligopeptides; Protein Kinase Inhibitors; Signal Transduction; Thalidomide | 2015 |
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Community Pharmacy Services; Fees, Pharmaceutical; Female; Humans; Lenalidomide; Male; Medication Adherence; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.
Topics: Adult; Anemia, Sickle Cell; beta-Globins; Carrier Proteins; Erythroid Precursor Cells; Erythropoiesis; Fetal Hemoglobin; gamma-Globins; Gene Expression Regulation, Developmental; Genetic Vectors; Hematopoietic Stem Cells; Histone Demethylases; Humans; Ikaros Transcription Factor; Kruppel-Like Transcription Factors; Lentivirus; Multiple Myeloma; Neoplasm Proteins; Nuclear Proteins; Proteasome Endopeptidase Complex; Repressor Proteins; RNA Interference; RNA, Small Interfering; SOXD Transcription Factors; Thalidomide; Transcription, Genetic | 2016 |
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2016 |
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Immunomodulation; Lenalidomide; Mice, SCID; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dexamethasone; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 2-Ring; Human Umbilical Vein Endothelial Cells; Humans; Multiple Myeloma; Neovascularization, Physiologic; Oligopeptides; Osteogenesis; Polycomb Repressive Complex 1; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thiazoles; Tumor Microenvironment | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Consensus; Cytogenetics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk Factors; Thalidomide; Transplantation, Autologous | 2016 |
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycine; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Thalidomide; Xenograft Model Antitumor Assays | 2016 |
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Kidney Diseases; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2017 |
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azetidines; Bortezomib; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Epigenomics; Heterografts; Humans; Hypoxia; Mice; Multiple Myeloma; Nitro Compounds; Thalidomide; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7 | 2016 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Lenalidomide; Life Expectancy; Male; Middle Aged; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Sweden; Thalidomide; Treatment Outcome | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Renal Insufficiency; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokines; Cyclin D1; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; Thalidomide; Tumor Microenvironment | 2016 |
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Thalidomide; Virus Activation; Virus Latency | 2016 |
The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Expansion of Th
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Th1 Cells; Thalidomide; Zoledronic Acid | 2017 |
Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis.
Topics: Aged; Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Renal Dialysis; Renal Insufficiency, Chronic; Thalidomide; Treatment Outcome | 2016 |
Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter.
Topics: Equipment Design; Humans; Immunologic Factors; Male; Membranes, Artificial; Middle Aged; Multiple Myeloma; Renal Dialysis; Thalidomide | 2017 |
Pomalidomide: when expectations are understated.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Retreatment; Thalidomide | 2017 |
Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Male; Multiple Myeloma; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retreatment; Thalidomide | 2017 |
Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Retrospective Studies; Thalidomide | 2017 |
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Kidney Function Tests; Male; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
New drugs in multiple myeloma and the significance of autologous stem cell transplants.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Stem Cell Transplantation; Thalidomide | 2009 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histones; Humans; Lenalidomide; Lymphoma; Multiple Myeloma; Oxidoreductases, N-Demethylating; Thalidomide; Transcription Factors | 2009 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Signal Transduction; Stromal Cells; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; T-Lymphocytes; Thalidomide | 2010 |
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Tolerance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Risk Assessment; Survival Rate; Thalidomide | 2010 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Topics: Apoptosis; Blotting, Western; CCAAT-Enhancer-Binding Protein-beta; Cell Separation; Down-Regulation; Eukaryotic Initiation Factor-4E; Flow Cytometry; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Immunohistochemistry; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Transfection | 2011 |
Acute lung toxicity related to pomalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Female; Humans; Lung; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Radiography; Thalidomide | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Novel therapeutics in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Vorinostat | 2012 |
Effective treatment of pomalidomide in central nervous system myelomatosis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
Pomalidomide and myeloma meningitis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Multiple Myeloma; Thalidomide | 2013 |
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Topics: Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL3; Coculture Techniques; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Integrin alpha4; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
Topics: Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2004 |
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Fibrin Fibrinogen Degradation Products; Hemostasis; Humans; Immunologic Factors; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transforming Growth Factor beta; Transforming Growth Factor beta2; Vascular Endothelial Growth Factor A; Venous Thrombosis | 2005 |
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
Topics: Angiogenesis Inhibitors; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Humans; Macrophage Colony-Stimulating Factor; Multiple Myeloma; Myeloid Progenitor Cells; NF-kappa B; Osteoclasts; Proto-Oncogene Proteins; Thalidomide; Trans-Activators | 2006 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |